Spero Therapeutics (SPRO) Receives FDA Fast Track Designation for SPR994 for treatment of cUTI and Acute Pyelonephritis - StreetInsider.com

Spero Therapeutics (SPRO) Receives FDA Fast Track Designation for SPR994 for treatment of cUTI and Acute Pyelonephritis  StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.



Comments

Popular posts from this blog

Summary of Society for Maternal-Fetal Medicine (SMFM) Consult Series #52: Diagnosis and management of fetal growth restriction - Contemporary Obgyn

Sarcoidosis: Causes, Symptoms, Diagnosis & Treatment